Canada

7 Vaccines Approved for Use in Canada

Protein Subunit

Novavax

Nuvaxovid

Approved in 37 countries
16 trials in 12 countries
Approval Source: covid-vaccine.canada.ca
VLP

Medicago

Covifenz

Approved in 1 country
6 trials in 6 countries
Approval Source: canada.ca
RNA

Moderna

Spikevax

Approved in 86 countries
67 trials in 23 countries
Approval Source: canada.ca
RNA

Pfizer/BioNTech

Comirnaty

Approved in 146 countries
84 trials in 27 countries
Approval Source: canada.ca
Non Replicating Viral Vector

Janssen (Johnson & Johnson)

Ad26.COV2.S

Approved in 111 countries
23 trials in 23 countries
Approval Source: canada.ca
Non Replicating Viral Vector

Oxford/AstraZeneca

Vaxzevria

Approved in 140 countries
64 trials in 31 countries
Approval Source: covid-vaccine.canada.ca
Non Replicating Viral Vector

Serum Institute of India

Covishield (Oxford/ AstraZeneca formulation)

Approved in 49 countries
4 trials in 1 country
Approval Source: theglobeandmail.com

12 in Clinical Trials in Canada

Protein Subunit

Novavax

Nuvaxovid

Approved in 37 countries
16 trials in 12 countries
VLP

Medicago

Covifenz

Approved in 1 country
6 trials in 6 countries
RNA

Moderna

Spikevax

Approved in 86 countries
67 trials in 23 countries
RNA

Pfizer/BioNTech

Comirnaty

Approved in 146 countries
84 trials in 27 countries
Non Replicating Viral Vector

Oxford/AstraZeneca

Vaxzevria

Approved in 140 countries
64 trials in 31 countries
Protein Subunit

University of Saskatchewan

COVAC-2

5 trials in 1 country
VLP

VBI Vaccines Inc

VBI-2902a

2 trials in 1 country
DNA

Entos Pharmaceuticals Inc

Covigenix VAX-001

2 trials in 1 country
RNA

Providence Therapeutics Holdings Inc.

PTX-COVID19-B

2 trials in 2 countries
Protein Subunit

University of Saskatchewan

COVAC-1

Non Replicating Viral Vector

McMaster University

Ad5-triCoV/Mac

Non Replicating Viral Vector

McMaster University

ChAd-triCoV/Mac